Acrivon Therapeutics Inc
Research Acrivon Therapeutics Inc (ACRV) on Bullrun: market cap USD 81.84M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACRV
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 81.84M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 17.96M
- Free cash flow-USD 14.95M
Valuation Snapshot
latest market cap is USD 81.84M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 77.91M | -USD 65.33M | n/a | -2.02 | USD 41.50M | USD 2.71M | USD 112.52M |
| FY2024 | USD 0 | -USD 80.56M | -USD 68.44M | n/a | -2.38 | USD 39.82M | USD 3.65M | USD 176.79M |
| FY2023 | USD 0 | -USD 60.39M | -USD 43.93M | n/a | -2.74 | USD 36.02M | USD 4.64M | USD 121.20M |
| FY2022 | USD 0 | -USD 31.17M | -USD 32.28M | n/a | -7.56 | USD 29.52M | USD 4.96M | USD 170.48M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 81.84M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 76.27M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 188.01M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 109.20M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 240.59M | n/a | n/a | n/a |
About Acrivon Therapeutics Inc
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Acrivon Therapeutics Inc's market cap?
Acrivon Therapeutics Inc's market capitalization is USD 81.84M.
What does Acrivon Therapeutics Inc do?
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.